Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

The effect of statins on mortality in patients with bacteremia.

Authors: Liappis, AP  Kan, VL  Rochester, CG  Simon, GL 
Citation: Liappis AP, etal., Clin Infect Dis. 2001 Oct 15;33(8):1352-7. Epub 2001 Sep 20.
Pubmed: (View Article at PubMed) PMID:11565076
DOI: Full-text: DOI:10.1086/323334

The statins, inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase, act to regulate the biosynthesis of cholesterol. Statins also deplete nonsterol cholesterol precursors, the isoprenoids, which are necessary for prenylation of critical membrane proteins that regulate cellular communication, including the inflammatory response. In a retrospective review of 388 bacteremic infections due to aerobic gram-negative bacilli and Staphylococcus aureus, there was a significant reduction in both overall (6% vs. 28%; P=.002) and attributable (3% vs. 20%; P=.010) mortality among patients taking statins compared with patients not taking statins. This reduction in mortality persisted in a multivariate analysis (odds ratio, 7.6; 95% confidence interval, 1.01-57.5). Among the statin group, diabetes, hypertension, and coronary artery disease were more prevalent (P<.001), and there were more skin and soft tissue infections identified as sources of bacteremia (P=.008). These data suggest a potential clinical role of statins in bacteremic infection; however, the mechanism by which mortality is reduced remains undefined.


Disease Annotations
Objects Annotated

Additional Information

RGD Object Information
RGD ID: 5508478
Created: 2011-10-18
Species: All species
Last Modified: 2011-10-18
Status: ACTIVE


RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.